Study: New blood sugar-lowering drug lowers risk of kidney and respiratory diseases – Xinhua English.news.cn

Study: New blood sugar-lowering drug lowers risk of kidney and respiratory disease 1/3/2023 13:14 A research team from the Department of Pharmacology and Pharmacology, Faculty of Medicine, HKU found that a new second-line hypoglycemic drug (sodium-glucose cotransporter 2 inhibitors, SGLT2i) for the treatment of type 2 diabetes can reduce the risk of kidney and respiratory diseases, Includes end-stage renal disease, obstructive airway disease, and pneumonia. The research results have been published in the internationally renowned scientific journal “The Journal of Clinical Endocrinology & Metabolism”. After adjusting for potential confounding factors in a group of more than 30,000 patients with type 2 diabetes, the research team found that a new generation of drugs can reduce the risk of end-stage renal disease by 81%, and reduce the risk of acute renal failure by 70%. A 50% reduction in the risk of developing albuminuria, as well as a slower rate of decline in glomerular filtration rate values, suggests a new generation of drugs that can provide additional protection for the kidneys. Studies have also found that the new drug can reduce the risk of obstructive airway disease, acute attack rate, and pneumonia by 35% to 46% in respiratory related diseases.